Amy Ronczka

Carisma Therapeutics (United States) — United States

Medicine · Health Sciences

6h-index111citations16works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(16), Monoclonal and Polyclonal Antibodies Research(12), Immune cells in cancer(7), Phagocytosis and Immune Regulation(5), Cancer Immunotherapy and Biomarkers(4)

Publications16 total

A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
Journal of Clinical Oncology·2023· 13 cited
Abstract CT241: A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors
Cancer Research·2023· 2 cited
634 A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts·2022· 8 citedOpen Access
633 A phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts·2022· 6 citedOpen Access
Abstract CT524: A phase 1, first in human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophages (CAR-M) in HER2-overexpressing solid tumors (ST)
Cancer Research·2022
A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors.
Journal of Clinical Oncology·2022· 42 cited
A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.
Journal of Clinical Oncology·2022· 2 cited
Abstract OT1-03-01: A phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors
Cancer Research·2022
A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.
Journal of Clinical Oncology·2022· 7 cited
951 A phase 1 first in human study of adenovirally transduced anti-HER2 CAR macrophages in subjects with HER2 overexpressing solid tumors: preliminary safety, pharmacokinetics, and TME reprogramming data
2021· 11 citedOpen Access
563TiP A phase I, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors
Annals of Oncology·2021
Abstract CT204: A phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors
Cancer Research·2021· 1 cited
A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.
Journal of Clinical Oncology·2021· 3 cited
a phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors
Cytotherapy·2021· 5 cited
Abstract OT-28-06: A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpressing solid tumors
Cancer Research·2021
Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide
Journal of Clinical Oncology·2008· 11 cited

Frequent Co-authors

Débora Barton(15), Daniel Cushing(14), Michael Klichinsky(14), Yuan Yuan(9), Elizabeth Claire Dees(8), Thomas Condamine(8), Yara Abdou(8), Naoto T. Ueno(7), Ramona F. Swaby(7), Kim A. Reiss(7), Mathew G. Angelos(6), Saar Gill(5), Kim Anna Reiss(4), Joseph Chao(4), Rehman Qureshi(4), Joshua Bauml(4), Melissa L. Johnson(3), Olga Shestova(3), Jonathan S. Serody(3), Saul J. Priceman(3)